Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy

Ovarian cancer is the most lethal gynecologic malignancy. About 75% of ovarian cancer patients relapse and/or develop chemo‐resistant disease after initial response to standard‐of‐care treatment with platinum‐based therapies. HER2 amplifications and overexpression in ovarian cancer are reported to v...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Faye R., Zhang, Piyan, Yang, Lin, Hou, Xiaonan, Leventakos, Konstantinos, Weroha, Saravut J., Vasmatzis, George, Kovtun, Irina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360362/
https://www.ncbi.nlm.nih.gov/pubmed/30499260
http://dx.doi.org/10.1002/1878-0261.12414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360362/
https://www.ncbi.nlm.nih.gov/pubmed/30499260
http://dx.doi.org/10.1002/1878-0261.12414

Ejemplares similares